1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

ALNY
Alnylam Pharmaceuticals, Inc.US flagNASDAQ Global Select
312.78
USD
+11.11
- -
41.76BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.77
0.68
0.49
0.55
0.99
0.74
2.01
4.29
7.13
8.53
14.64
17.61
28.35
32.53
Basic EPS, GAAP
-1.45
-4.85
-3.45
-4.79
-5.42
-7.57
-8.11
-7.46
-7.2
-9.3
-3.52
-2.18
2.39
4.38
Free Cash Flow per Basic Share
-1.18
-2.35
-2.41
-4.35
-5.38
-6.85
-3.83
-5.96
-6.06
-5.04
0.34
-0.33
3.55
4.88
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-9.68
-12.87
-14.83
-19.35
-23.71
-28.23
-34.1
-39.87
-45.9
-53.97
-56.11
-57.08
-51.15
-49.28
Tangible Book Value per Share
4.39
12.6
15.06
10.75
19.51
12.94
13.17
8.84
4.97
-1.3
-1.77
0.53
6.02
8.16
Basic Weighted Avg Shares
62
74
84
86
91
101
109
115
118
122
125
128
131
132
Sales/Revenue/Turnover
47
51
41
47
90
75
220
493
844
1,037
1,828
2,248
3,714
4,287
Operating Margin (%)
-197.05
-364.34
-720.27
-900.33
-556.2
-1,087.56
-427.5
-168.09
-83.93
-75.68
-15.43
-7.87
13.51
17.54
Depreciation Expense
10
12
19
15
12
15
54
74
90
44
54
57
56
55
Net Income, GAAP
-89
-360
-290
-410
-491
-761
-886
-858
-853
-1,131
-440
-278
314
577
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.91
1.57
Profit Margin (%)
-189.17
-712.79
-705.83
-869.63
-545.95
-1,016.58
-403.24
-174.15
-101.01
-109.04
-24.08
-12.37
8.45
13.46
Working Capital
200
651
1,043
540
1,620
1,021
1,363
2,030
2,113
1,924
2,015
2,109
2,584
2,870
LT Debt
- -
- -
- -
150
30
30
276
484
957
1,278
1,264
1,254
1,233
1,227
Total Equity
270
936
1,265
920
1,766
1,302
1,439
1,016
588
-158
-221
67
789
1,075
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
28.39
39.32
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-9.8
-15.2
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
45
46
46
LT Borrowings
1,040
1,008
1,009
LT Finance Leases
223
225
218
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
132
132
133
Market Capitalization
59,546
52,090
43,609

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3,953
4,051
4,219
Cash, Cash Equivalents & STI
2,725
2,908
3,009
Accounts Receivable, Net
965
778
884
Inventories
75
83
84
Total Current Liabilities
1,555
1,466
1,349
Payables & Accruals
1,271
939
1,073
ST Debt
45
46
46
Deferred Revenue
3
5
3

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
83.59%
163.27%
1,076.33%
Free Cash Flow
-132.99%
-302.18%
-1,192.73%
Net Income, GAAP
-14.93%
-55.74%
-212.79%
Sales/Revenue/Turnover
66.49%
51.72%
65.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
494
660
501
593
2,248
2025
594
774
1,249
1,097
3,714
2026
1,167
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.52
-0.13
-0.87
- -
-2.18
2025
-0.14
-0.51
1.91
1.41
2.39
2026
1.55
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Yvonne L. Greenstreet
Full Time Employees
2,230
Sector
Healthcare
Industry
Biotechnology
Address
675 West Kendall Street Cambridge MA United States of America 02142
IPO Date
Jun 1, 2004
CIK
0001178670
Website
alnylam.com
Similar Companies
Sagimet Biosciences Inc. (SGMT)
Kuros Biosciences AG (CSBTF)
AgeX Therapeutics, Inc. (AGE)
LAVA Therapeutics N.V. (LVTX)
Nanosynth Group Plc (RMS.L)
Tyra Biosciences, Inc. (TYRA)
Business
Alnylam Pharmaceuticals, Inc. (ALNY) develops and commercializes RNA interference (RNAi) therapeutics targeting genetically defined diseases; core products include ONPATTRO (patisiran) for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, AMVUTTRA (vutrisiran) for ATTR amyloidosis with polyneuropathy or cardiomyopathy, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1; the company also advances partnered programs such as Leqvio (inclisiran) for hypercholesterolemia marketed by Novartis. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam operates globally with key facilities in the US, Europe (including France, Italy, Netherlands, Sweden, Switzerland, and the UK), and Japan. The company maintains strategic collaborations with Roche on zilebesiran for hypertension, Regeneron for CNS diseases, Sanofi on fitusiran for hemophilia, and others including Novartis and Agios Pharmaceuticals. Recent developments encompass expansion of AMVUTTRA into ATTR cardiomyopathy with strong launch uptake and upgraded 2025 revenue guidance, initiation of a Phase 1 trial for ALN-4324 targeting GRB14 for type 2 diabetes, and Agios' IND clearance for AG-236 (ALN-TMP) in polycythemia vera; Alnylam joined the Alliance for Genomic Discovery in 2025 to leverage datasets for gene-silencing medicines and extended its partnership with Medison Pharma into LATAM and APAC markets. Pipeline advancements feature nucresiran for ATTR amyloidosis, mivelsiran for Alzheimer's disease and cerebral amyloid angiopathy, and positive Phase 3 data for zilebesiran. These efforts support Alnylam's transition to profitability with 2024 net product revenues exceeding $1.3 billion across rare and cardiometabolic indications.

Company News

APIChatGPT

  • fool.com

    Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

  • seekingalpha.com

    Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript

  • businesswire.com

    Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

  • zacks.com

    Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

  • forbes.com

    The Healthcare M&A Wave

  • zacks.com

    Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term

  • zacks.com

    Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

  • businesswire.com

    Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

  • businesswire.com

    GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

  • seekingalpha.com

    Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

  • marketbeat.com

    Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts

  • barrons.com

    Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

  • zacks.com

    Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development

  • benzinga.com

    Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion

  • reuters.com

    Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

  • businesswire.com

    Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

  • businesswire.com

    Alnylam Issues 2025 Corporate Responsibility Report

  • 247wallst.com

    Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More

  • seekingalpha.com

    Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • marketbeat.com

    Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build